Written | 2011-07 | Pascal Gelebart, Hanan Armanious, Raymond Lai |
Department of Laboratory Medicine, Pathology, University of Alberta, Room 1466, 11560 University Avenue, T6G 1Z2-Edmonton, Alberta, Canada |
Identity |
Alias (NCBI) | AD10 | CD156c | HsT18717 | MADM | kuz |
HGNC (Hugo) | ADAM10 |
HGNC Alias symb | kuz | MADM | HsT18717 | CD156C |
HGNC Previous name | a disintegrin and metalloproteinase domain 10 |
LocusID (NCBI) | 102 |
Atlas_Id | 44397 |
Location | 15q21.3 [Link to chromosome band 15q21] |
Location_base_pair | Starts at 58588809 and ends at 58749707 bp from pter ( according to GRCh38/hg38-Dec_2013) [Mapping ADAM10.png] |
Fusion genes (updated 2017) | Data from Atlas, Mitelman, Cosmic Fusion, Fusion Cancer, TCGA fusion databases with official HUGO symbols (see references in chromosomal bands) |
ADAM10 (15q21.3) / ANKRD11 (16q24.3) | ADAM10 (15q21.3) / FIZ1 (19q13.42) | ADAM10 (15q21.3) / RER1 (1p36.32) | |
ADAM10 (15q21.3) / ZNF770 (15q14) | CYBB (Xp11.4) / ADAM10 (15q21.3) |
DNA/RNA |
![]() | |
Figure 1. Representation of the ADAM10 gene organization. | |
Description | The gene spans a region of 15.36 kb and the coding part is divided into 16 exons. |
Transcription | Only one type of transcript has been described. The 2247-nucleotide transcript encodes a protein of 748 amino acid residues. The first and last exons are partially untranslated. |
Pseudogene | None described so far. |
Protein |
![]() | |
Figure 2. Crystal structure of ADAM10 Disintegrin and cysteine-rich domain at 2.9 A resolution. Adapted from PDB (access number: 2AO7). | |
Description | ADAM10 is a metalloproteinase composed of 748 residues. |
![]() | |
Figure 3. ADAM10 tissue expression profile. Adapted from GeneAtlas U113A. | |
Expression | ADAM10 RNA has been reported to be present in wide range of human tissue (Yanai et al., 2005). Data obtained from GeneAtlas have shown that ADAM10 transcript is the most highly expressed in myeloid, NK cells and monocytes as well as cardiomyocytes and smooth muscle cells (figure 3). At the protein level, ADAM10 has been reported in epithelials tissue of the heart, liver and kidney (Hall and Erickson, 2003). |
Localisation | ADAM10 is localized at the plasma membrane. However, nuclear localization of ADAM10 has been reported in prostate cancer and in mantle cell lymphoma cells (Armanious et al., 2011). |
![]() | |
Figure 4. ADAM10 protein structure organization. | |
Function | ADAM10 belongs to the family of metalloproteinases (Chantry et al., 1989; Chantry and Glynn, 1990; Edwards et al., 2008). ADAM10 protein is composed of multiple functional domains that include: a prodomain, a catalytic domain, a cysteine-rich domain, a transmembraneous domain, a cytoplasmic domain and a SH3 domain (Seals and Courtneidge, 2003; Edwards et al., 2008) (see figure 4). ADAM10 is synthesized as a pro-protein and therefore needs to be cleaved to be activated (Anders et al., 2001). Two proteins, the convertase 7 and the furin, have been implicated in the activation of ADAM10 (Anders et al., 2001). To date the major function of ADAM10 appears to be attributed to its enzymatic activity as a metalloproteinase. In fact, ADAM10 is involved in the intra-membrane proteolysis process, whereby it mediates ectodomain shedding of various membrane bound receptors, adhesion molecules, growth factors and cytokines like TNF-alpha (Rosendahl et al., 1997; Lunn et al., 1997; Hikita et al., 2009; Mezyk-Kopec et al., 2009), Notch (Hartmann et al., 2002; Gibb et al., 2010), E-cadherin (Maretzky et al., 2005), Ephrin (Janes et al., 2005), HER-2 (Liu et al., 2006), CD30 (Eichenauer et al., 2007), CD44 (Anderegg et al., 2009) and IL-6 receptor to name a few. The functional role of the SH3 domains of ADAM10 has never been studied. Moreover, the recent observation that ADAM10 can be found in the nucleus of some cells raises the possibility of new and uncovers function of ADAM10 (Arima et al., 2007). ADAM10 seems to be detrimental for embryogenesis as the knockout mice for ADAM10 die at day 9.5 of embryogenesis (Hartmann et al., 2002). The mice present several developmental defects in the nervous central system as well in the cardiovascular system. This latest observation correlates well with the fact that ADAM10 transcript is highly expressed in cardiomyocyte. In human, ADAM10 was recently been demonstrated to be a regulator of the lymphocyte development (Gibb et al., 2011). |
Mutations |
Note | No mutation has been reported so far. |
Implicated in |
Note | |
Entity | Various cancers |
Note | ADAM family members have been recently involved in malignant progression and development (Mochizuki and Okada, 2007; Rocks et al., 2008; Wagstaff et al., 2011; Duffy et al., 2009). ADAM10 has been shown to be constitutively active in a number of solid tumors, and this biochemical defect is implicated in the pathogenesis of many tumors. The following paragraphs will summarize what has been discovered about the function of ADAM10 in cancer. |
Entity | Brain tumors |
Note | ADAM10 protein has been reported to be highly expressed in the human central nervous system (Kärkkäinen et al., 2000). Recently, two different studies (Kohutek et al., 2009; Formolo et al., 2011) have uncovered the function of ADAM10 in the cell migration and invasiveness process of glioblastoma cells. In fact the authors have shown that ADAM10 by mediating the cleavage of N-cadherin was found to regulate the migratory properties of glioblastoma cells (Kohutek et al., 2009). On the other hand, the protein expression of ADAM10 was found to be higher in cell with strong invasiveness capability. |
Entity | Prostate cancer |
Note | Prostate cancer is one of the most frequent cancers in men. The cause of prostate cancer development is unknown but is likely to be arising from several factors. Development of prostate cancer is androgen-dependent in early stages of the disease but cell growth became androgen-independent. ADAM10 have been found to be expressed in all prostate tumor samples (Karan et al., 2003). Interestingly, McCulloch et al. have observed that ADAM10 expression was up-regulated by androgen stimulation. Those observations were confirmed in a study published by Arima et al. However, in this work they reveal that ADAM10 was predominantly localized in the nucleus of cancer cells and show that ADAM10 can co-immunoprecipitate with androgen receptor in the nucleus. Moreover, they also observed that nuclear expression of ADAM10 was correlating with several biological parameters like the Gleason score and prostate specific antigen expression. Inhibition of ADAM10 expression by a siRNA approach was able to induce a cell proliferation decrease of prostate cancer cells. This study suggests for the first time that ADAM10 may have some function in the nucleus by regulating androgen receptor function. |
Entity | Breast cancer |
Note | Expressions of different members of the ADAM family have been investigated in breast cancer. Despite that some ADAM family members present differential expression between non neoplastic and breast cancer tissue, no difference was observed for ADAM10 (Lendeckel et al., 2005). Nevertheless, Liu and co-workers have recently described than ADAM10 was the principal responsible for HER2 shedding in HER2 over-expressing breast cancer. The cleavage of HER2 liberates the extracellular domain of HER2 leaving a p95 fragment containing the transmembrane domain as well as the intracellular domain. This p95 fragment presents constitutive kinase activation and its expression correlates with a poor prognosis. The author demonstrated that in conjunction with low amount of HER2 inhibitor, ADAM10 inhibition was inducing a decrease in cell proliferation. |
Entity | Colon and gastric and oral carcinomas |
Note | Deregulation of ADAM10 in colon cancer development has been reported in several studies. Knösel et al. have reported that ADAM10 expression in colorectal cancer patient samples, detectable by immunohistochemistry was found to correlate with higher clinical stage. Moreover, it has been demonstrated that xenografting of colorectal cancer cells with enforced expression of ADAM10 in nude mice induced formation of liver metastasis compared to the negative control cells, and this effect can be attributed to ADAM10-mediated cleavage and release of L1-CAM, a cell adhesion molecule (Gavert et al., 2007). Similarly to Knösel et al., ADAM10 expression was associated with gastric cancer progression and correlates with worst prognostic outcome (Wang et al., 2011). Using immunohistochemistry, it was also found that ADAM10 is over-expressed in squamous cell carcinomas of the oral cavity, as compared to the benign epithelial cells; knockdown of ADAM10 expression using siRNA in the cell lines derived from those tumors induces a significant decrease in cell growth (Ko et al., 2007). |
Entity | Melanoma, pancreatic cancer and adenoid cystic carcinoma |
Note | The expression of ADAM10 has been investigated in melanoma and Lee et al. have reported that ADAM10 is over-expressed in melanoma metastasis in comparison to primary melanoma cells. Similar findings were made in pancreatic cancer, where inhibition of ADAM10 expression in pancreatic carcinoma cell lines also resulted in a significant decrease in invasiveness and migration (Gaida et al., 2010). |
Entity | Hematologic malignancies |
Note | Recently, Armanious et al. have described for the first time the function of ADAM10 in non solid tumors. They have reported that ADAM10 is constitutively activated and over-expressed in different form of B-cell lymphoma like mantle cell lymphoma and diffuse large B-cell lymphoma. Moreover, the authors have described that inhibition of ADAM10 leads to a decrease of cell proliferation. On the other hand, stimulation of mantle cells with the recombinant active form of ADAM10 increases further their proliferation. Additionally, they also demonstrated, as reported previously in the literature, that ADAM10 was responsible for the release of active from of TNF-alpha that in turn was contributing to the activation of the NF-kappab pathways. |
To be noted |
To summarize, the function of ADAM protein family members emerge as an important player in the pathobiology of various form of cancers. Therefore, they represent today a new therapeutic target of choice for cancer therapy. In particular, ADAM10 is the object of intense drug development (Soundararajan et al., 2009; Crawford et al., 2009; Yavari et al., 1998; Moss et al., 2008). |
Bibliography |
ADAM10 is the constitutive functional sheddase of CD44 in human melanoma cells. |
Anderegg U, Eichenberg T, Parthaune T, Haiduk C, Saalbach A, Milkova L, Ludwig A, Grosche J, Averbeck M, Gebhardt C, Voelcker V, Sleeman JP, Simon JC. |
J Invest Dermatol. 2009 Jun;129(6):1471-82. Epub 2008 Oct 30. |
PMID 18971959 |
Regulation of the alpha-secretase ADAM10 by its prodomain and proprotein convertases. |
Anders A, Gilbert S, Garten W, Postina R, Fahrenholz F. |
FASEB J. 2001 Aug;15(10):1837-9. |
PMID 11481247 |
Nuclear translocation of ADAM-10 contributes to the pathogenesis and progression of human prostate cancer. |
Arima T, Enokida H, Kubo H, Kagara I, Matsuda R, Toki K, Nishimura H, Chiyomaru T, Tatarano S, Idesako T, Nishiyama K, Nakagawa M. |
Cancer Sci. 2007 Nov;98(11):1720-6. Epub 2007 Aug 28. |
PMID 17727679 |
Constitutive activation of metalloproteinase ADAM10 in mantle cell lymphoma promotes cell growth and activates the TNFalpha/NFkappaB pathway. |
Armanious H, Gelebart P, Anand M, Belch A, Lai R. |
Blood. 2011 Jun 9;117(23):6237-46. Epub 2011 Mar 25. |
PMID 21441465 |
A novel metalloproteinase originally isolated from brain myelin membranes is present in many tissues. |
Chantry A, Glynn P. |
Biochem J. 1990 May 15;268(1):245-8. |
PMID 1693075 |
ADAM10 as a therapeutic target for cancer and inflammation. |
Crawford HC, Dempsey PJ, Brown G, Adam L, Moss ML. |
Curr Pharm Des. 2009;15(20):2288-99. (REVIEW) |
PMID 19601831 |
The role of ADAMs in disease pathophysiology. |
Duffy MJ, McKiernan E, O'Donovan N, McGowan PM. |
Clin Chim Acta. 2009 May;403(1-2):31-6. (REVIEW) |
PMID 19408347 |
The ADAM metalloproteinases. |
Edwards DR, Handsley MM, Pennington CJ. |
Mol Aspects Med. 2008 Oct;29(5):258-89. Epub 2008 Aug 15. (REVIEW) |
PMID 18762209 |
ADAM10 inhibition of human CD30 shedding increases specificity of targeted immunotherapy in vitro. |
Eichenauer DA, Simhadri VL, von Strandmann EP, Ludwig A, Matthews V, Reiners KS, von Tresckow B, Saftig P, Rose-John S, Engert A, Hansen HP. |
Cancer Res. 2007 Jan 1;67(1):332-8. |
PMID 17210715 |
Secretome signature of invasive glioblastoma multiforme. |
Formolo CA, Williams R, Gordish-Dressman H, MacDonald TJ, Lee NH, Hathout Y. |
J Proteome Res. 2011 Jul 1;10(7):3149-59. Epub 2011 May 31 |
PMID 21574646 |
Expression of A disintegrin and metalloprotease 10 in pancreatic carcinoma. |
Gaida MM, Haag N, Gunther F, Tschaharganeh DF, Schirmacher P, Friess H, Giese NA, Schmidt J, Wente MN. |
Int J Mol Med. 2010 Aug;26(2):281-8. |
PMID 20596609 |
Expression of L1-CAM and ADAM10 in human colon cancer cells induces metastasis. |
Gavert N, Sheffer M, Raveh S, Spaderna S, Shtutman M, Brabletz T, Barany F, Paty P, Notterman D, Domany E, Ben-Ze'ev A. |
Cancer Res. 2007 Aug 15;67(16):7703-12. |
PMID 17699774 |
ADAM10 is essential for Notch2-dependent marginal zone B cell development and CD23 cleavage in vivo. |
Gibb DR, El Shikh M, Kang DJ, Rowe WJ, El Sayed R, Cichy J, Yagita H, Tew JG, Dempsey PJ, Crawford HC, Conrad DH. |
J Exp Med. 2010 Mar 15;207(3):623-35. Epub 2010 Feb 15. |
PMID 20156974 |
The emergence of ADAM10 as a regulator of lymphocyte development and autoimmunity. |
Gibb DR, Saleem SJ, Chaimowitz NS, Mathews J, Conrad DH. |
Mol Immunol. 2011 Jun;48(11):1319-27. Epub 2011 Jan 13. (REVIEW) |
PMID 21236490 |
ADAM10 is expressed in human podocytes and found in urinary vesicles of patients with glomerular kidney diseases. |
Gutwein P, Schramme A, Abdel-Bakky MS, Doberstein K, Hauser IA, Ludwig A, Altevogt P, Gauer S, Hillmann A, Weide T, Jespersen C, Eberhardt W, Pfeilschifter J. |
J Biomed Sci. 2010 Jan 13;17:3. |
PMID 20070888 |
ADAM 10: an active metalloprotease expressed during avian epithelial morphogenesis. |
Hall RJ, Erickson CA. |
Dev Biol. 2003 Apr 1;256(1):146-59. |
PMID 12654298 |
The disintegrin/metalloprotease ADAM 10 is essential for Notch signalling but not for alpha-secretase activity in fibroblasts. |
Hartmann D, de Strooper B, Serneels L, Craessaerts K, Herreman A, Annaert W, Umans L, Lubke T, Lena Illert A, von Figura K, Saftig P. |
Hum Mol Genet. 2002 Oct 1;11(21):2615-24. |
PMID 12354787 |
Involvement of a disintegrin and metalloproteinase 10 and 17 in shedding of tumor necrosis factor-alpha. |
Hikita A, Tanaka N, Yamane S, Ikeda Y, Furukawa H, Tohma S, Suzuki R, Tanaka S, Mitomi H, Fukui N. |
Biochem Cell Biol. 2009 Aug;87(4):581-93. |
PMID 19767822 |
Adam meets Eph: an ADAM substrate recognition module acts as a molecular switch for ephrin cleavage in trans. |
Janes PW, Saha N, Barton WA, Kolev MV, Wimmer-Kleikamp SH, Nievergall E, Blobel CP, Himanen JP, Lackmann M, Nikolov DB. |
Cell. 2005 Oct 21;123(2):291-304. |
PMID 16239146 |
Expression of ADAMs (a disintegrin and metalloproteases) and TIMP-3 (tissue inhibitor of metalloproteinase-3) in human prostatic adenocarcinomas. |
Karan D, Lin FC, Bryan M, Ringel J, Moniaux N, Lin MF, Batra SK. |
Int J Oncol. 2003 Nov;23(5):1365-71. |
PMID 14532978 |
Metalloprotease-disintegrin (ADAM) genes are widely and differentially expressed in the adult CNS. |
Karkkainen I, Rybnikova E, Pelto-Huikko M, Huovila AP. |
Mol Cell Neurosci. 2000 Jun;15(6):547-60. |
PMID 10860581 |
Immunoprofiles of 11 biomarkers using tissue microarrays identify prognostic subgroups in colorectal cancer. |
Knosel T, Emde A, Schluns K, Chen Y, Jurchott K, Krause M, Dietel M, Petersen I. |
Neoplasia. 2005 Aug;7(8):741-7. |
PMID 16207476 |
Increase of disintergin metalloprotease 10 (ADAM10) expression in oral squamous cell carcinoma. |
Ko SY, Lin SC, Wong YK, Liu CJ, Chang KW, Liu TY. |
Cancer Lett. 2007 Jan 8;245(1-2):33-43. Epub 2005 Nov 23. |
PMID 16309826 |
ADAM-10-mediated N-cadherin cleavage is protein kinase C-alpha dependent and promotes glioblastoma cell migration. |
Kohutek ZA, diPierro CG, Redpath GT, Hussaini IM. |
J Neurosci. 2009 Apr 8;29(14):4605-15. |
PMID 19357285 |
Tissue inhibitor of metalloproteinases-1 promotes liver metastasis by induction of hepatocyte growth factor signaling. |
Kopitz C, Gerg M, Bandapalli OR, Ister D, Pennington CJ, Hauser S, Flechsig C, Krell HW, Antolovic D, Brew K, Nagase H, Stangl M, von Weyhern CW, Brucher BL, Brand K, Coussens LM, Edwards DR, Kruger A. |
Cancer Res. 2007 Sep 15;67(18):8615-23. |
PMID 17875701 |
ADAM10 is upregulated in melanoma metastasis compared with primary melanoma. |
Lee SB, Schramme A, Doberstein K, Dummer R, Abdel-Bakky MS, Keller S, Altevogt P, Oh ST, Reichrath J, Oxmann D, Pfeilschifter J, Mihic-Probst D, Gutwein P. |
J Invest Dermatol. 2010 Mar;130(3):763-73. Epub 2009 Oct 29. |
PMID 19865098 |
Increased expression of ADAM family members in human breast cancer and breast cancer cell lines. |
Lendeckel U, Kohl J, Arndt M, Carl-McGrath S, Donat H, Rocken C. |
J Cancer Res Clin Oncol. 2005 Jan;131(1):41-8. Epub 2004 Sep 30. |
PMID 15565459 |
Identification of ADAM10 as a major source of HER2 ectodomain sheddase activity in HER2 overexpressing breast cancer cells. |
Liu PC, Liu X, Li Y, Covington M, Wynn R, Huber R, Hillman M, Yang G, Ellis D, Marando C, Katiyar K, Bradley J, Abremski K, Stow M, Rupar M, Zhuo J, Li YL, Lin Q, Burns D, Xu M, Zhang C, Qian DQ, He C, Sharief V, Weng L, Agrios C, Shi E, Metcalf B, Newton R, Friedman S, Yao W, Scherle P, Hollis G, Burn TC. |
Cancer Biol Ther. 2006 Jun;5(6):657-64. Epub 2006 Jun 14. |
PMID 16627989 |
Purification of ADAM 10 from bovine spleen as a TNFalpha convertase. |
Lunn CA, Fan X, Dalie B, Miller K, Zavodny PJ, Narula SK, Lundell D. |
FEBS Lett. 1997 Jan 6;400(3):333-5. |
PMID 9009225 |
ADAM10 mediates E-cadherin shedding and regulates epithelial cell-cell adhesion, migration, and beta-catenin translocation. |
Maretzky T, Reiss K, Ludwig A, Buchholz J, Scholz F, Proksch E, de Strooper B, Hartmann D, Saftig P. |
Proc Natl Acad Sci U S A. 2005 Jun 28;102(26):9182-7. Epub 2005 Jun 15. |
PMID 15958533 |
Expression of the disintegrin metalloprotease, ADAM-10, in prostate cancer and its regulation by dihydrotestosterone, insulin-like growth factor I, and epidermal growth factor in the prostate cancer cell model LNCaP. |
McCulloch DR, Akl P, Samaratunga H, Herington AC, Odorico DM. |
Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):314-23. |
PMID 14734484 |
Identification of ADAM10 as a major TNF sheddase in ADAM17-deficient fibroblasts. |
Mezyk-Kopec R, Bzowska M, Stalinska K, Chelmicki T, Podkalicki M, Jucha J, Kowalczyk K, Mak P, Bereta J. |
Cytokine. 2009 Jun;46(3):309-15. Epub 2009 Apr 5. |
PMID 19346138 |
ADAMs in cancer cell proliferation and progression. |
Mochizuki S, Okada Y. |
Cancer Sci. 2007 May;98(5):621-8. Epub 2007 Mar 9. (REVIEW) |
PMID 17355265 |
ADAM10 as a target for anti-cancer therapy. |
Moss ML, Stoeck A, Yan W, Dempsey PJ. |
Curr Pharm Biotechnol. 2008 Feb;9(1):2-8. (REVIEW) |
PMID 18289051 |
Emerging roles of ADAM and ADAMTS metalloproteinases in cancer. |
Rocks N, Paulissen G, El Hour M, Quesada F, Crahay C, Gueders M, Foidart JM, Noel A, Cataldo D. |
Biochimie. 2008 Feb;90(2):369-79. Epub 2007 Sep 2. (REVIEW) |
PMID 17920749 |
Identification and characterization of a pro-tumor necrosis factor-alpha-processing enzyme from the ADAM family of zinc metalloproteases. |
Rosendahl MS, Ko SC, Long DL, Brewer MT, Rosenzweig B, Hedl E, Anderson L, Pyle SM, Moreland J, Meyers MA, Kohno T, Lyons D, Lichenstein HS. |
J Biol Chem. 1997 Sep 26;272(39):24588-93. |
PMID 9305925 |
The ADAMs family of metalloproteases: multidomain proteins with multiple functions. |
Seals DF, Courtneidge SA. |
Genes Dev. 2003 Jan 1;17(1):7-30. (REVIEW) |
PMID 12514095 |
Triptolide: An inhibitor of a disintegrin and metalloproteinase 10 (ADAM10) in cancer cells. |
Soundararajan R, Sayat R, Robertson GS, Marignani PA. |
Cancer Biol Ther. 2009 Nov;8(21):2054-62. Epub 2009 Nov 14. |
PMID 19783906 |
The roles of ADAMTS metalloproteinases in tumorigenesis and metastasis. |
Wagstaff L, Kelwick R, Decock J, Edwards DR. |
Front Biosci. 2011 Jan 1;16:1861-72. (REVIEW) |
PMID 21196270 |
ADAM 10 is associated with gastric cancer progression and prognosis of patients. |
Wang YY, Ye ZY, Li L, Zhao ZS, Shao QS, Tao HQ. |
J Surg Oncol. 2011 Feb;103(2):116-23. doi: 10.1002/jso.21781. Epub 2010 Nov 23. |
PMID 21259244 |
Inhibiting adenoid cystic carcinoma cells growth and metastasis by blocking the expression of ADAM 10 using RNA interference. |
Xu Q, Liu X, Chen W, Zhang Z. |
J Transl Med. 2010 Dec 20;8:136. |
PMID 21171968 |
Genome-wide midrange transcription profiles reveal expression level relationships in human tissue specification. |
Yanai I, Benjamin H, Shmoish M, Chalifa-Caspi V, Shklar M, Ophir R, Bar-Even A, Horn-Saban S, Safran M, Domany E, Lancet D, Shmueli O. |
Bioinformatics. 2005 Mar 1;21(5):650-9. Epub 2004 Sep 23. |
PMID 15388519 |
Human metalloprotease-disintegrin Kuzbanian regulates sympathoadrenal cell fate in development and neoplasia. |
Yavari R, Adida C, Bray-Ward P, Brines M, Xu T. |
Hum Mol Genet. 1998 Jul;7(7):1161-7. |
PMID 9618175 |
Citation |
This paper should be referenced as such : |
Gelebart, P ; Armanious, H ; Lai, R |
ADAM10 (ADAM metallopeptidase domain 10) |
Atlas Genet Cytogenet Oncol Haematol. 2012;16(1):1-6. |
Free journal version : [ pdf ] [ DOI ] |
External links |
REVIEW articles | automatic search in PubMed |
Last year publications | automatic search in PubMed |
© Atlas of Genetics and Cytogenetics in Oncology and Haematology | indexed on : Thu Mar 25 19:54:28 CET 2021 |
For comments and suggestions or contributions, please contact us